ECSP10010717A - Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina - Google Patents

Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Info

Publication number
ECSP10010717A
ECSP10010717A EC2010010717A ECSP10010717A ECSP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC 2010010717 A EC2010010717 A EC 2010010717A EC SP10010717 A ECSP10010717 A EC SP10010717A EC SP10010717 A ECSP10010717 A EC SP10010717A
Authority
EC
Ecuador
Prior art keywords
dosage form
pharmaceutical dosage
immediate release
indoline derivative
methyl
Prior art date
Application number
EC2010010717A
Other languages
English (en)
Inventor
Roman Messerschmid
Peter Lach
Torsten Sokoliess
Peter Stopfer
Dirk Trommeshauser
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41017080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010717(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP10010717A publication Critical patent/ECSP10010717A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Educational Administration (AREA)
  • Biomedical Technology (AREA)
  • Educational Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una forma de dosificación farmacéutica que suministra un perfil de liberación inmediata que contiene la sustancia activa 3-Z-[1-(4-(N-((4-metil-piperazin-1-il)-metilcarbonil)-N-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato.
EC2010010717A 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina ECSP10010717A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08157750 2008-06-06

Publications (1)

Publication Number Publication Date
ECSP10010717A true ECSP10010717A (es) 2011-02-28

Family

ID=41017080

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010717A ECSP10010717A (es) 2008-06-06 2010-12-23 Forma de dosificación farmaceutica para la liberación inmediata de un derivado de indolina

Country Status (35)

Country Link
US (3) US20110190318A1 (es)
EP (1) EP2313087B2 (es)
JP (2) JP5583119B2 (es)
KR (1) KR20110022586A (es)
CN (1) CN102056599A (es)
AR (1) AR072060A1 (es)
AU (1) AU2009254556B2 (es)
BR (1) BRPI0913235A2 (es)
CA (1) CA2726648A1 (es)
CL (1) CL2010001362A1 (es)
CO (1) CO6280468A2 (es)
CY (1) CY1121272T1 (es)
DK (1) DK2313087T4 (es)
EA (1) EA201001857A1 (es)
EC (1) ECSP10010717A (es)
ES (1) ES2711913T5 (es)
FI (1) FI2313087T4 (es)
HR (1) HRP20190181T4 (es)
HU (1) HUE042524T2 (es)
IL (1) IL209055A0 (es)
LT (1) LT2313087T (es)
MA (1) MA32386B1 (es)
MX (1) MX338001B (es)
PE (1) PE20100050A1 (es)
PL (1) PL2313087T5 (es)
PT (1) PT2313087T (es)
RS (1) RS58280B2 (es)
SG (1) SG191607A1 (es)
SI (1) SI2313087T2 (es)
TR (1) TR201901579T4 (es)
TW (1) TW201002692A (es)
UA (1) UA107560C2 (es)
UY (1) UY31876A (es)
WO (1) WO2009147220A1 (es)
ZA (1) ZA201007972B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077604A1 (en) 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
EP3004224B1 (en) 2013-06-04 2022-01-26 Monosol, LLC Water-soluble film sealing solutions, related methods, and related articles
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
CN108135737B (zh) 2015-06-06 2021-11-05 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
BR112018074450A2 (pt) 2016-06-02 2019-03-19 Cloudbreak Therapeutics, Llc composições e métodos para a utilização de nintedanib para melhorar o sucesso da cirurgia do glaucoma
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法
EP3600322A1 (en) 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
LT3700529T (lt) 2017-10-23 2025-10-10 Naujas veikliųjų medžiagų derinys, skirtas progresuojančių fibrozinių intersticinių plaučių ligų (pf-ild) gydymui
CU24684B1 (es) 2018-03-07 2023-10-06 Pliant Therapeutics Inc Compuestos de aminoácidos como inhibidores de la integrina
CN115361950A (zh) 2020-04-01 2022-11-18 勃林格殷格翰国际有限公司 生物标记物在治疗纤维化病症中的用途
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
JP2025525881A (ja) 2022-08-16 2025-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 眼内使用するためのニンテダニブの医薬製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169398B1 (de) 1984-07-24 1990-08-29 R.P. Scherer GmbH Oxytetracyclin-HC1-Weichgelatinekapseln und Verfahren zu ihrer Herstellung
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2629249C (en) * 2005-11-11 2015-05-05 Boehringer Ingelheim International Gmbh Combination treatment of cancer comprising egfr/her2 inhibitors
PL2299987T3 (pl) * 2008-06-06 2018-08-31 Boehringer Ingelheim International Gmbh Farmaceutyczna postać dawkowania w formie kapsułki zawierająca formulację zwiesiny pochodnej indolinonu
MX338047B (es) * 2008-06-06 2016-03-31 Boehringer Ingelheim Int Combinacion farmaceutica útil para el tratamiento fr enfermedades que involucran proliferación celular, migración o apoptosis de células de mieloma, angiogéneisis o fibrosis.
JP2012515184A (ja) * 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2429520A1 (en) * 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
DK2313087T3 (en) 2019-02-18
JP5992937B2 (ja) 2016-09-14
US20130203773A1 (en) 2013-08-08
JP2014098045A (ja) 2014-05-29
ES2711913T3 (es) 2019-05-08
LT2313087T (lt) 2019-02-25
CO6280468A2 (es) 2011-05-20
JP5583119B2 (ja) 2014-09-03
EP2313087B1 (en) 2018-11-21
FI2313087T4 (fi) 2023-12-28
CL2010001362A1 (es) 2011-05-13
AR072060A1 (es) 2010-08-04
AU2009254556A1 (en) 2009-12-10
UA107560C2 (uk) 2015-01-26
RS58280B1 (sr) 2019-03-29
PL2313087T3 (pl) 2019-05-31
MX2010013092A (es) 2011-02-25
BRPI0913235A2 (pt) 2016-01-19
TR201901579T4 (tr) 2019-02-21
UY31876A (es) 2010-01-29
RS58280B2 (sr) 2024-02-29
SI2313087T2 (sl) 2024-03-29
SG191607A1 (en) 2013-07-31
SI2313087T1 (sl) 2019-03-29
KR20110022586A (ko) 2011-03-07
AU2009254556B2 (en) 2015-08-20
PL2313087T5 (pl) 2024-03-04
ZA201007972B (en) 2011-07-27
TW201002692A (en) 2010-01-16
ES2711913T5 (es) 2024-06-24
EP2313087B2 (en) 2023-11-22
HRP20190181T4 (hr) 2024-07-05
JP2011522010A (ja) 2011-07-28
DK2313087T4 (da) 2024-01-15
PE20100050A1 (es) 2010-01-29
PT2313087T (pt) 2019-02-15
WO2009147220A1 (en) 2009-12-10
EA201001857A1 (ru) 2011-06-30
EP2313087A1 (en) 2011-04-27
US20140163040A1 (en) 2014-06-12
HRP20190181T1 (hr) 2019-03-22
IL209055A0 (en) 2011-01-31
CN102056599A (zh) 2011-05-11
CA2726648A1 (en) 2009-12-10
CY1121272T1 (el) 2020-05-29
MA32386B1 (fr) 2011-06-01
HUE042524T2 (hu) 2019-07-29
US20110190318A1 (en) 2011-08-04
MX338001B (es) 2016-03-30

Similar Documents

Publication Publication Date Title
UY31876A (es) Forma de dosificación farmacéutica para la liberación inmediata de un derivado de indolinona
ECSP10010660A (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspención de un derivado de indolinona
DOP2012000051A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
UY32351A (es) Compuestos de pirimidinil indol para uso como inhibidores de atr
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
FR2928836B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
CU20110113A7 (es) Lactamas como inhibidores beta secretasa
UY32299A (es) Composiciones farmacéuticas líquidas
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
TN2010000555A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
CU23604B7 (es) Compuestos terapéuticos
CY1114956T1 (el) Νεες συνθεσεις 1-[2-(2,4-διμεθυλο-φαινυλοσουλφανυλο)-φαινυλο]πιπεραζινης
CY1114060T1 (el) Φαρμακευτικες μορφες δοσολογιας